Biotech | April 06, 2026
Enveric Biosciences bags key US patent for mental health drug
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
IND application for EB-003 expected in early 2026
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Athena is also exploring the use of this technology for expanded carrier screening
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
